BJMO - volume 8, issue 1, march 2014
D. Schrijvers MD, PhD, A. Vandebroek MD, N. Blockx MD, F. van Fraeyenhove MD
Bone complications are frequently observed in cancer patients. They may be the result of the disease or due to the anticancer treatment. Osteoporosis is seen in up to 30% of cancer patients depending on tumor type and treatment and screening for osteoporosis is indicated in selected patients. It should be prevented by the use of calcium and vitamin D and exercising programs and, if present, should be adequately treated by drugs registered for the treatment of osteoporosis. Bone metastases are observed in up to 75% of metastatic cancer patients depending on the tumor type. Skeletal-related complications, occurring in 50–70% in patients with bone metastases, can be prevented and delayed by the use of bisphosphonates or denosumab. Prevention of the development of bone metastases has been shown by anti-tumor treatment while the role of modification of the micro-environment by bisphosphonates and denosumab needs further study.
(BELG J MED ONCOL 2014;8(1):3–8)
Read more
BJMO - volume 6, issue 6, december 2012
D. Schrijvers MD, PhD, D. van den Weyngaert MD, O. Lenssen MD, S. De Clercq , D. De Surgeloose MD
Recurrent giant cell tumour of the bone is a difficult to treat and mutilating disease. A patient with a recurrent giant cell tumour of the jaw is reported. He received multiple treatments with surgery and bisphosphonates. Due to progressive disease he was treated with denosumab with good result. An overview of giant cell tumour of the bone is given. (BELG J MED ONCOL 2012;6:201–203)
Read moreBJMO - volume 6, issue 4, september 2012
D. Schrijvers MD, PhD
Guidelines are important tools in relation to patient treatment and care in oncology. They are systematically developed statements to assist practitioner- and patient-decisions about appropriate health care for specific clinical circumstances. They are needed because of unexplained and inappropriate variations in clinical practice patterns, different cancer treatment outcomes, further limitations in resources affecting administration of high quality health care, difficulties of integrating rapidly evolving scientific evidence into daily clinical practice, guidance for involved stakeholders and quality control. A guideline development programme should be inclusive, transparent, consultative, evidence-based and adhering to internationally recognised standards of practice such as the AGREE Collaboration. There should be an implementation plan to ensure that guidelines are implemented in daily clinical practice since they have an important influence on cancer outcome. This article reviews the need, development, implementation, adherence and outcome of guidelines. (BELG J MED ONCOL 2012;6:112–117)
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.